Annual General Meeting of Shareholders in Active Biotech 29 March 2001

3/30/2001 4:01 AM EST

At Active Biotech AB´s Annual General Meeting Sven Andréasson, Mats
Arnhög, Maria Borelius, Svend Holst-Nielsen, Mats Pettersson, Peter
Sjöstrand and Hugo Thelin were re-elected. Hugo Thelin will continue
serving as Chairman of the Board.

Anders Williamsson and Håkan Åström, who have renounced a re-election
due to other commitments, were thanked for their services by the
Chairman of the Board, HugoThelin.

The President & CEO, Sven Andréasson´s speech at the General Meeting is
available for download (as well as the Annual Report) on our web-site
www.activebiotech.com.

Lund 30 March 2001
Active Biotech AB (Publ)

Sven Andréasson
President & CEO

Active Biotech AB is a biotechnology company focusing on research and
development of medicines and vaccines. Our expertise lies in the
knowledge of the human immune defence system. We have a high-quality
project portfolio and financial strength. The most important products
and projects are medicines for multiple sclerosis (SAIK) and cancer
(TTS), the SBL Cholera Vaccine, and Dukoral and ETEC vaccines against
tourist diarrhoea. Active Biotech's turnover was MSEK 280 in 2000.

Active Biotech AB
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50
e-mail